ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
People With Newly Diagnosed T2DM Showed Significant Improvement in Glycemic Control and Effective Weight Management After Completion of Fitterfly Diabetes Digital Therapeutics Program
Tejal Lathia 1 , Ritika Verma 2 , Abdul Khader Mohammed 3 , Chitra Selvan 4 , Dwarakanath C S 5 , Ajay Aggarwal 6 , Gayatri Ghanekar 7 , Beena Bansal 8 , Ramesh Goyal 9 , Shilpa Joshi 10 & Arbinder Singal 11
1Apollo Hospital, Department of Endocrinology and Diabetology, Navi Mumbai, India; 2Fitterfly Healthtech Pvt Ltd, Scientific writing and Research, Navi Mumbai, India; 3Fitterfly Healthtech Pvt Ltd, Scientific Writing and Research, Navi Mumbai, India; 4MS Ramaiah Memorial Hospital, Department of Endocrinology and Diabetology, Bengaluru, India; 5Apollo Hospital, Department of Endocrinology, Bangalore, India; 6Dr Ajay Aggarwal - Diabetes, Thyroid & Hormone Centre, Department of Endocrinology, Delhi, India; 7Fortis Hospital, Department of Endocrinology, Kalyan, India; 8Door to Care, Department of Endocrinology, Haryana, India; 9Krish Speciality Clinic/Endocrine Solutions, Department of Endocrinology, Ahmedabad, India; 10Fitterfly Healthtech Pvt Ltd, Department of Metabolic Nutrition, Navi Mumbai, India; 11Fitterfly Healthtech Pvt Ltd, Chief Executive Officer, Navi Mumbai, India
Background and aim: Early glycemic control and weight reduction in diabetes has been associated with prevention of progression of β-cell dysfunction and reduction in diabetes-related complications. Digital therapeutics (DTx) platforms can provide evidence-based therapeutic interventions to improve glycemic control using sustainable behavior change. This study aims at assessing the real-world effectiveness of the Fitterfly Diabetes program in improving glycemic control and weight management among people with newly diagnosed T2DM.
Methods: De-identified data of 102 participants with T2DM (diabetes duration <1 year, mean age: 42.96 ± 11.54 years, gender: 30.39% (31/102) female) was analyzed. All the participants completed 90-days on the program and were provided with the Fitterfly mobile application for digital logging of meals and physical activity, remote lifestyle coaching, and live video consultations by experts (psychologists, physiotherapist and nutritionist). The participants were divided into 3 categories based on baseline BMI: normal (≤ 22.9 kg/m2), overweight (23.0-24.9 kg/m2), and obese (≥25.00 kg/m2). The outcomes were evaluated at beginning and end of the program. All the data has been shown as median (IQR).
Results: Among all the participants, the baseline median HbA1c, weight, and BMI was found to be 7.00 (6.30, 8.52) %, 76.20 (70.00, 87.25) kg, and 27.70 (24.64, 30.90) kg/m2 respectively. Reduction in HbA1c, weight, and BMI was observed by -0.75 (-2.30, -0.20) %, -3.00 (-5.00, -1.00) kg, and -1.00 (-1.88, -0.39) kg/m2 respectively (P<0.0001 for all). Among participants with baseline HbA1c of ≤ 6.4 %, 6.5-8.4%, 8.5-10.5%, and ≥10.6% the reduction in HbA1c was observed by -0.20 (-0.30, 0.00) %, -0.70 (-1.40, -0.30) %, -2.95 (-3.45, -2.15) %, and -5.50 (-6.40, -3.85) % respectively (P<0.01 for all). After completion of program, 70.59 % (72/102) participants had achieved recommended HbA1c value ≤ 6.5 %. Reduction in BMI among participants in normal, overweight, and obese category was observed by -0.77 (-1.06, -0.10) kg/m2, -0.69 (-1.34, 0.15) kg/m2 and -1.20 (-1.96, -0.46) kg/m2 (P<0.01 for all) respectively.
Conclusion: The Fitterfly Diabetes DTx program led to improved glycemic control and effective weight management among people with newly diagnosed T2DM. The program can help in providing continuous support for implementing lifestyle changes and can help in holistic management of diabetes.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more